Inside the $230 billion our new Longevity Biotech Report says the pipeline is already worth – no regulatory rewrite required.

Phil Newman analyzes Oura’s IPO and lawsuit, movement context in dementia, GenFlow dog trial, Rentosertib aging clocks, and ...

Telomir’s oncology compound helped fish with age-related retinal damage see better and moved two aging-linked markers toward ...

Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same ...

Enveda raised $311 million to push its AI-discovered medicines forward, including one aimed at life after GLP-1 drugs.

A new connector lets Function Health members bring lab results and biomarker trends straight into Meta’s personal AI agent, ...

Seoul biotech’s redesigned method makes circular RNA up to seven times more efficient to build, widening what RNA medicine can treat.

LOY-003, a daily tablet for large and giant breeds, has earned RXE acceptance, the third such milestone for a Loyal lifespan ...

Belgian clinical data show Allegro’s nanotech injection Hydrocelin delivers lasting knee osteoarthritis relief from a single ...

With one in five citizens now 65 or older, Taiwan’s largest healthy-aging expo argued that older adults are a workforce to ...

NKGen presented new clinical data on troculeucel’s potential in Alzheimer’s, Parkinson’s and frontotemporal dementia.

Our new Longevity Biotech Report puts a number on longevity's payoff – and asks who actually gets to cash it in.